Lataa...

PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates

PF-05231023, a long-acting FGF21 analogue, is a promising potential pharmacotherapy for the treatment of obesity and associated comorbidities. Previous studies have shown the potential of FGF21 and FGF21-like compounds to decrease body weight in mice, non-human primates, and humans; the precise mech...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Pharmacokinet Pharmacodyn
Päätekijät: Thompson, W. Clayton, Zhou, Yingjiang, Talukdar, Saswata, Musante, Cynthia J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2016
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4954843/
https://ncbi.nlm.nih.gov/pubmed/27405817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10928-016-9481-1
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!